Premium
Intraoperative Ir‐192 implantation for early breast cancer: Techniques and results
Author(s) -
Mansfield Carl M.
Publication year - 1990
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19900701)66:1<1::aid-cncr2820660102>3.0.co;2-x
Subject(s) - medicine , lumpectomy , breast cancer , surgery , radiation therapy , cancer , mastectomy
Patients with early breast cancer (T1‐2 NO‐1) can be treated by lumpectomy and irradiation with a local control and survival equal to more radical surgery. Between 1982 and 1988, 323 patients with early breast cancer were treated, when possible, with Ir‐192 implants at the time of lumpectomy to a local dose of 2000 cGy in 40‐50 hours. Ten to 14 days later, the whole breast was treated to 4500 cGy at 180 per fraction in 5 weeks. The 6‐year actuarial survival for stages I and II disease was 98% and 91%, respectively, and the recurrence‐free survival was 96% and 98%, respectively. When these 323 patients were evaluated by T status, a local control of 97% was the same for T1 and T2 lesions. The cosmetic results were good to excellent in 95% of the patients. This approach has improved our ability to accurately place the boost dose in the breast.